Greenwich LifeSciences files to expand patent for lead immunotherapy to cover non-HLA-A*02 breast cancer patients

Greenwich LifeSciences, Inc. (USA, Nasdaq: GLSI) announced new patent claims for its Fast Track-designated asset GLSI-100, a peptide-based immunotherapy composed of the GP2 antigen and the adjuvant GM-CSF, targeting breast cancer recurrence prevention in HER2-positive patients. The claims, filed with patent authorities and not yet granted, are grounded in statistically significant open-label immune response and recurrence rate data from the ongoing Phase III FLAMINGO-01 trial (NCT05232916). The filing seeks to extend coverage to non-HLA-A02 patients, a population previously outside the primary scope of the program. If granted following successful prosecution, the patent would provide protection through 2045.

GLSI-100 operates through antigen-specific cellular immunity. GP2 is a 9 amino acid transmembrane peptide derived from the HER2/neu protein, a cell surface receptor overexpressed in a subset of breast cancers. When administered with GM-CSF as an immunologic adjuvant, the formulation is designed to prime and expand HER2-specific cytotoxic T cells capable of recognizing and eliminating residual HER2-expressing tumor cells following surgery and standard HER2-directed therapy. The mechanism does not inhibit HER2 signaling directly but instead recruits the adaptive immune system to establish durable post-surgical surveillance against minimal residual disease.

The original clinical rationale for GLSI-100 centered on HLA-A02-positive patients, as GP2 was initially characterized as an epitope presented by the HLA-A02 allele. The new patent claims assert clinical benefit in non-HLA-A02 patients based on data from the open-label arm of FLAMINGO-01, in which 250 non-HLA-A02 patients were enrolled and all received GLSI-100. A preliminary analysis of recurrence rates following the Primary Immunization Series, defined as the first six injections administered over six months, showed an approximately 80% reduction in recurrence rate in this cohort. The company states that the immune response trajectory and safety profile in non-HLA-A02 patients trend similarly to the HLA-A02 arms of FLAMINGO-01 and to the earlier Phase IIb study. The company has noted that this data is preliminary, not fully reviewed, and not a prediction of final study outcomes.

The Phase IIb study, conducted at 16 sites led by MD Anderson Cancer Center, enrolled 46 HER2/neu 3+ overexpressor patients treated with GLSI-100 and 50 placebo-treated patients receiving GM-CSF alone. After five years of follow-up, an 80% or greater reduction in metastatic breast cancer recurrence rate was observed in treated patients who completed the Primary Immunization Series and remained disease-free over the first six months. The FLAMINGO-01 Phase III trial is designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, with 28 events required for primary analysis and an interim analysis for superiority and futility triggered at 14 events.

The AllSci BriefSystematic R&D and deal news. Daily.

The US FDA has reviewed protocol changes permitting enrollment of both HLA-A02 and non-HLA-A02 patients into the same randomized arms of FLAMINGO-01, which the company states is already under way at US sites. Greenwich LifeSciences has indicated it will pursue the option of a combined analysis of both patient groups, which the company estimates could expand the addressable patient population by approximately 88,000 patients per year across the US and Europe. The company also plans to expand its immunologic analysis by sequencing T cell receptor DNA at baseline and post-treatment to characterize the dynamics of GP2-specific T cell responses over time. Specific clinical results for the blinded HLA-A02 arms of FLAMINGO-01 remain undisclosed, and the company states that the open-label analysis was conducted in a manner that maintains the study blind.

Context and competitive landscape

The GLSI-100 breast cancer immunotherapy program occupies a mechanistic space distinct from the dominant HER2-targeting modalities currently in clinical use. Where trastuzumab (Herceptin, Roche, Switzerland) and pertuzumab (Perjeta, Roche, Switzerland) function as monoclonal antibodies blocking HER2 extracellular domain signaling, and where trastuzumab deruxtecan (Enhertu, AstraZeneca/Daiichi Sankyo, UK/Japan) delivers cytotoxic payload via HER2-directed antibody-drug conjugate, GLSI-100 operates entirely through the induction of antigen-specific cellular immunity. In the adjuvant and recurrence-prevention setting, trastuzumab-based regimens are the established standard of care following surgery, and FLAMINGO-01 enrolls patients who have already completed neoadjuvant and postoperative adjuvant trastuzumab-based treatment, positioning GLSI-100 as a post-standard-of-care maintenance immunotherapy rather than a direct replacement.

A mechanistic comparator in the HER2 vaccine space is HER-Vaxx (IMU-131), developed by Imugene Limited (Australia), a B-cell peptide vaccine targeting the HER2 extracellular domain designed to elicit anti-HER2 antibody responses rather than cytotoxic T cell responses. HER-Vaxx has been evaluated in Phase II in gastric cancer. The mechanistic distinction is relevant: GLSI-100 targets T cell-mediated cytotoxicity via MHC class I presentation of an intracellular HER2 peptide, while HER-Vaxx targets humoral immunity against the extracellular domain.

The patent application, solely owned by Greenwich LifeSciences, remains subject to prosecution. No grant has been confirmed, and protection through 2045 is contingent on successful examination.